Andrew Dudum

Like, the indications are so numerous that I think it's just more advantageous for the population and probably for the overall cost of healthcare if it's treated like a preventative sort of medicine.

HIMSS CEO Andrew Dudum said he expects cash pay prices for GLP-1s to fall to $40 to $50 per month, I think by 2030 or fast-forwarding five years.

Do you think it'll be there as well, $40, $50 a month?

I think that's probably right.

Management alignment is a very strong 8 out of 10.

CEO Andrew Dudum holds Class V stock carrying 175 votes per share.

That gives him over 50% voting power.

So he has ultimate control, which is great for long-term vision and keeps alignment strong.

And Jack too is a visionary.

The same is true of Andrew Dudum and the people he surrounded himself with at HIMSS.

It just seemed inevitable to me.

And I think if you believe that the thing you're building is an inevitability and is a category creator and a category winner, It doesn't have to be a first player, as I'm all in on Team Legora, but it has to be inevitable.